Still some work for the SP to do driven by stars aligning for...

Still some work for the SP to do driven by stars aligning for the following - trials to start and progress through recruitment, acceptable trial results, a Big Pharma based on results making the decision to make an offer for partnership or buyout and of course shareholders understanding the value of what RACE have.

With that disclaimer above in mind, the AML part of Pillar 3 could be worth as much as the buyout for Forty Seven last year. On my calculations the AML part of Pillar 3 alone could be worth to shareholders at least $37 per share ( requires a strong trials result and a large majority of shareholders to not accept offers that could be below intrinsic value ).

The other columns in this table are other buyouts mapped into RACE's pillars as it helps to understand potential value if results from trials are successful.



1. https://www.gilead.com/news-and-press/press-room/press-releases/2020/3/gilead-to-acquire-forty-seven-for-49-billion
2. https://www.investors.com/news/technology/biotech-company-gilead-buy-forty-seven-ftsv-stock-soars/
3. https://www.fiercebiotech.com/special-report/immunomedics-top-10-takeover-targets-biopharma
4. https://www.cancer.org/cancer/breast-cancer/understanding-a-breast-cancer-diagnosis/types-of-breast-cancer/triple-negative.html
5. RACE Oncology AGM 2020
6. https://www.reuters.com/article/us-loxo-oncology-m-a-lilly-idUSKCN1P10YZ
7. https://www.fiercepharma.com/marketing/array-s-colorectal-cancer-data-shows-why-pfizer-splashed-11b-for-biotech
8. https://xconomy.com/national/2015/03/05/abbvie-snaps-up-pharmacyclics-pays-whopping-21b-for-cancer-drug/
9. https://endpts.com/gsk-bags-tesaro-for-5b-as-it-leaps-into-commercial-oncology-and-beefs-up-cancer-drug-pipeline/